Comparative Pharmacology
Head-to-head clinical analysis: DENAVIR versus VEKLURY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENAVIR versus VEKLURY.
DENAVIR vs VEKLURY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DENAVIR is a synthetic peptide that inhibits viral replication by preventing the fusion of the viral envelope with the host cell membrane. It specifically targets the HIV-1 envelope glycoprotein gp41, blocking the conformational changes required for membrane fusion.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
5 mg applied topically to affected area once daily for 4 weeks.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
None Documented
None Documented
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function. Prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Renal excretion of unchanged drug accounts for approximately 90% of the administered dose via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Category C
Category C
Antiviral
Antiviral